Report Interpretation

Overview

This earnings review argues that WuXi AppTec’s strong 1H26 execution, higher management guidance and sustained demand across its service lines justify higher earnings estimates and target prices. Citi retains Buy ratings on both the Shanghai- and Hong Kong-listed shares.

Core views

Citi characterizes WuXi AppTec’s 1H26 result as a strong beat, driven by demand across all business segments and a greater number of late-stage CMO projects. Management raised 2026 revenue guidance to Rmb58.5–60.5bn and expects continuing-operations revenue growth of 35%–39% year on year, including a 3–5 percentage-point impact from US-dollar depreciation. At constant exchange rates, continuing-business backlog grew about 30% year on year in 1H26, while new orders signed rose more than 40%, which Citi views as support for continued growth visibility. The report identifies small-molecule CDMO as the principal near-term growth engine. Small-molecule D&M business revenue grew 73% year on year in 1H26, which management attributed mainly to 15 new commercial and Phase 3 projects. Mid- to late-stage pipeline revenue now exceeds half of total revenue, and more than 80% of late-stage and commercial projects originated from the internal early-stage pipeline. Citi also notes that WuXi Chemistry was operating at full capacity, while the company plans to bring forward a new Changzhou site with both small-molecule and TIDES capacity. WuXi Testing grew 31.5% year on year, with drug-safety evaluation services up 42.8%; Citi links this to biotech-funding recovery and increased AI drug-discovery needs. Fair-value gains on biological assets were limited to Rmb265mn in 1H26. High demand is also leading to increased investment. Management raised 2026 capex guidance to Rmb7.5–8.5bn from Rmb6.5–7.5bn. The company targets 130,000L of solid-phase peptide synthesizer total reactor volume for TIDES by 2026; small-molecule API reactor volume had exceeded 4,000kL by 2025 and is targeted at 5,000kL in 2026. Taixing and Singapore sites are expected to become operational in 2027 and 2028, respectively. Citi also highlights AI drug discovery as a demand driver: AI technologies are accelerating novel-compound identification, while customers use WuXi AppTec’s high-throughput platforms to generate data that refine their AI models and support more complex-molecule projects. Reflecting the raised guidance and expected margin improvement, Citi increases revenue forecasts for 2026, 2027 and 2028 by 8% each and raises EPS forecasts by 18%, 19% and 15%, respectively. It retains Buy ratings on both share classes and lifts the A-share target price to Rmb188 from Rmb160 and the H-share target price to HK$215 from HK$183. The targets are based on an NPV-based SOTP valuation using a 9.2% WACC, 1.0 beta and 3% terminal growth rate, with segment forecasts extending to 2035E.

Analysis framework

Citi starts with the 1H26 earnings beat, management guidance, backlog and order trends, then connects segment growth and capacity investment to its forward revenue and margin assumptions. It revises earnings forecasts and values the company through a segment-by-segment NPV-based sum-of-the-parts framework.

Methodology notes

• Valuation methodsSOTP (Sum-of-the-Parts) Valuation

  NPV-based sum-of-the-parts valuation

  Citi values WuXi AppTec by estimating the value of its operating segments and other items separately, then combining them into a per-share target price.

• Valuation methodsDCF (Discounted Cash Flow)

  Net-present-value analysis using a 9.2% WACC, 1.0 beta and 3% terminal growth

  The report discounts projected segment economics through 2035E to present value; the discount rate and terminal-growth assumption are key inputs to its target prices.

• Industry AnalysisUpstream-Midstream-Downstream Transmission

  Early-stage pipeline conversion into late-stage and commercial projects

  Citi uses the proportion of late-stage projects originating internally to explain how early discovery work can feed higher-value downstream manufacturing revenue.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• WuXi AppTec (603259.SH)

  Primary covered A-share; Citi retains Buy and raises the target price following stronger operating momentum.

  Strengths

  Broad demand, 73% yoy small-molecule D&M growth, late-stage project conversion and expanding capacity.

  Risks

  Demand reductions, talent retention challenges, regulatory issues, overseas expansion execution, audit standards, labor costs and US sanctions.

• WuXi AppTec (02359.HK)

  Primary covered H-share; Citi retains Buy and raises the target price following stronger operating momentum.

  Strengths

  Broad demand, 73% yoy small-molecule D&M growth, late-stage project conversion and expanding capacity.

  Risks

  Demand reductions, talent retention challenges, regulatory issues, overseas expansion execution, audit standards, labor costs and US sanctions.

Key data

• 2026 revenue guidanceRmb58.5–60.5bnContinuing-operations revenue growth guidance of 35%–39% year on year, including a 3–5ppt impact from US-dollar depreciation.
• Continuing-business backlog growthApproximately 30% yoy at constant exchange rates1H26 growth.
• New orders signedMore than 40% yoy1H26 growth.
• Small-molecule D&M revenue growth73% yoy1H26; management cited 15 new commercial and Phase 3 projects.
• WuXi Testing revenue growth31.5% yoy1H26; drug-safety evaluation services grew 42.8% yoy.
• 2026 capex guidanceRmb7.5–8.5bnRaised from Rmb6.5–7.5bn.
• Revenue forecast revision+8% for 2026E/2027E/2028EReflects higher guidance.
• EPS forecast revision+18%/+19%/+15% for 2026E/2027E/2028EReflects higher revenue and margin assumptions.

Impact & implications

Citi views stronger order intake, backlog growth, late-stage project conversion and capacity expansion as supporting a higher earnings trajectory. Its higher forecasts and valuation lead to increased target prices while maintaining Buy ratings on both listed share classes.

Risks

• Customer spending and demand for outsourced discovery, testing, development and manufacturing could decline.
• The company may be unable to attract, train, motivate or retain skilled scientists and research technicians.
• Regulatory or industry-standard compliance failures, or adverse actions by drug-approval authorities, could harm reputation, operations and financial condition.
• Expansion into new geographic markets may not succeed or operate effectively.
• Failure to meet customer audit and inspection standards could impair client service.
• Higher labor costs could pressure profitability.
• US sanctions are an explicit downside risk.

What to watch

• Management’s delivery against 2026 revenue guidance of Rmb58.5–60.5bn.
• Continuing-business backlog and new-order growth.
• Conversion of early-stage work into late-stage and commercial projects.
• Execution of Changzhou, TIDES, Taixing and Singapore capacity expansion plans.
• Demand for drug-safety evaluation and AI-enabled drug-discovery services.